Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chloroxine in preparing anti-angiogenesis medicine

An anti-angiogenesis and chloroxin technology, applied in the field of medicine, can solve problems such as chloroxin that has not yet been seen, and achieve the effects of good development prospects, wide source of raw materials and high safety

Inactive Publication Date: 2013-04-24
HANGZHOU LEISUO PHARMA
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] There are no relevant reports on the anti-angiogenesis activity of clooxacin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chloroxine in preparing anti-angiogenesis medicine
  • Application of chloroxine in preparing anti-angiogenesis medicine
  • Application of chloroxine in preparing anti-angiogenesis medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 Qualitative observation of the inhibitory effect of clooxine on zebrafish intersegmental vessel (ISV) generation

[0040] Zebrafish:

[0041] The zebrafish used in this example is vascular transgenic green fluorescent zebrafish (a gene specifically expressed by zebrafish endothelial cells acts as a driver to drive the specific expression of green fluorescent protein in zebrafish vascular endothelial cells) （ figure 1 ） , Feeding and use standards are strictly in accordance with the requirements of the American Institutional Animal Care and Use Committee (IACUC).

[0042] Fish water:

[0043] Preparation method: Add 0.3g of Instant Ocean salts to 1L of reverse osmosis (RO) water.

[0044] Dimethyl sulfoxide (DMSO, analytically pure):

[0045] Purchased from Aladdin (Catalog #1095515, Lot #30573). 0.1% DMSO solution (negative control) Preparation: When in use, prepare a working solution with a concentration of 0.1% with fish farming water,...

Embodiment 2

[0056] Example 2 Quantitative evaluation of the inhibitory effect of clooxacin on zebrafish intersegmental vessel (ISV) generation

[0057] The budding of zebrafish vascular endothelial cells starts at 20hpf after fertilization, forms the main intersegmental vascular network at about 30-31hpf, such as dorsal long axis vessels (DLAV) and intersegmental vessels (ISV), and basically forms a complete body axis at 48hpf Vascular network [27] , the intact intersegmental vessels (ISVs) are clearly visible at this time. The complete intersegmental vessel mainly refers to the segment of vessel connecting the dorsal aorta (DA) and the dorsal long axis vessel (DLAV), see figure 1 (48hpf vascular transgenic fluorescent zebrafish body intersegmental vessel model). There are 28 pairs of intact intersegmental vessels (ISVs) in 48hpf zebrafish. The experimental method is as follows:

[0058] (1) Experimental grouping and embryo treatment: 270 well-developed zebrafish embryos were ta...

Embodiment 3

[0067] Example 3 Qualitative observation of the inhibitory effect of clooxacin on the generation of zebrafish inferior intestinal vessels (SIV)

[0068] The zebrafish subintestinal vessel (SIV, subintestinal vessel) grows on both sides of the yolk sac, and its shape is like a basket. The length of the subintestinal vessel (SIV) extending downward from the ventral side of the somites is about 50-100 μm [15-16] . See Figure 4 (72hpf vascular transgenic fluorescent zebrafish subintestinal vascular model). The experimental method is as follows:

[0069](1) Experimental grouping and embryo treatment: 45 well-developed zebrafish embryos were taken, and the embryo development phase was 48hpf (hour-postfertilization, hpf) after fertilization, and were randomly divided into 3 groups (negative control group, drug group, positive control group) group), and the number of embryos in each group was 15. During the operation, the embryos were evenly distributed to 48-well cell cultur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of chloroxine in preparing anti-angiogenesis medicine. Until now no relevant reports about the anti-angiogenesis activity of the chloroxine are available. The invention provides the application of chloroxine in preparing anti-angiogenesis medicines, anti-tumor medicines and medicines for preventing wet age-related macular degeneration. The in-vivo pharmacodynamic experiment using a zebra fish angiogenesis model shows that the chloroxine can remarkably suppress zebra fish angiogenesis, remarkably suppress the growth of transplanted human tumor cells and has a therapeutic effect to wet age-related macular degeneration. Therefore, the chloroxine can be used for preparing anti-angiogenesis medicines, anti-tumor medicines and medicines for preventing wet age-related macular degeneration.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of clooxine in the preparation of anti-angiogenesis drugs. Background technique [0002] Angiogenesis is highly related to many major human diseases, such as malignant tumors, age-related macular degeneration (Age-related macular degeneration, AMD), atherosclerosis (Atherosclerosis), rheumatoid arthritis (Rheumatoid arthritis), diabetes Retinal degeneration (Diabetic retinopathy) and tumor metastasis (Tumor metastasis), etc. [1] . With the gradual increase of the aging population in China, these major diseases have seriously endangered the life and health of the people of our country. [0003] In 1971, Professor Judah Folkman of Harvard University proposed anti-tumor blood vessel therapy for the first time. He believed that the growth and spread of solid tumors depended on the formation of new blood vessels in the tumor and obtained nutrients through the new bl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/47A61P35/00A61P27/02A61P9/10A61P19/02A61P29/00A61P3/10A61P35/04
Inventor 李春启朱晓宇朱凤刘洪翠
Owner HANGZHOU LEISUO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com